Abbreviations: BM = bone marrow; BU = busulphan; CHT = chemotherapy.
Post-remission strategy for acute myeloid leukemia (AML) is matter of intense debate. The currently available options are represented by intensive standard chemotherapy, autologous (auto-HSCT) and allogeneic stem cell transplantation (allo-HSCT). Allo-HSCT is the most effective treatment to prevent leukemia relapse; however, it is associated with high non-relapse mortality (NRM) rates and risk of developing GvHD. Auto-HSCT is an alternative approach, able to provide an acceptable long-term outcome with lower NRM rates and better quality of life for survivors, compared with allo-HSCT. 1 However, there are concerns about high relapse incidence, due to the lack of GvL effect and the possibility of graft contamination by leukemic stem cells, which could potentially contribute to relapse. Several randomized trials and meta-analyses have reported better leukemia-free survival (LFS) following auto-HSCT compared with conventional chemotherapy, 2 while recent studies [3] [4] [5] [6] failed to show a significant difference in overall survival (OS) between auto-and allo-HSCT. We herein report the results of a retrospective analysis performed on a large homogeneous cohort of AML patients autografted in first complete remission (CR1). We included 809 consecutive AML patients receiving auto-HSCT in CR1 in 72 GITMO centers between 1985 and 2008; patients having M3 AML were excluded. Median age at transplant was 47 years (range 16-75), while median year of transplant was 2001 (range 1985-2008) . All patients were evaluable for cytogenetic data. Cytogenetic risk categories were defined as follows: i-good risk group, including patients bearing t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22) or normal karyotype with mutant NPM1 and wild type FLT3-ITD; ii-poor risk group, including patients bearing complex karyotype, inv(3) (q21q26)/t(3;3)(q21;q26) − 5,-5q, − 7,-7q, other 11q23 abn, inv(3) (q21q26.2), t(3;3)(q21q26.2), t(6;9), t(9;22), abn(17p), or normal karyotype in the presence of FLT3-ITD; iii-intermediate risk group, including patients with cytogenetics abnormalities not encompassed in good or poor risk group in the absence of NPM1 mutation or FLT3-ITD. Cytogenetic risk was good, intermediate and poor in 131 (16%), 544 (67%) and 134 (17%) of patients, respectively. NPM and FLT3 mutational status was available in 170 (39%) of patients with normal karyotype, who were accordingly included in good risk (NPM+/FLT3 − ), poor risk (FLT3+) or intermediate risk (NPM − /FLT3 − ), respectively. Two hundred and seventy patients bearing normal karyotype were unavailable for molecular evaluation, and were therefore included in the intermediate risk category. Median interval from diagnosis to transplant was 171 days (range 14-9451); conditioning regimen was chemotherapy busulphan-based, chemotherapy not busulphan-based and TBI-based in 56%, 30% and 9% of patients, respectively; in 37 patients the conditioning regimen was unknown. Stem cell source was bone marrow (BM) or peripheral blood stem cells (PBSCs) in 32% and 68% of patients respectively. The characteristics of the patients are summarized in Table 1 .
Survival curves were estimated by the Kaplan-Meier method, and the log-rank test was used for univariate comparisons. Cumulative incidence curves were used for relapse incidence and non-relapse mortality in a competing risks setting, where the risks of death in CR and relapse were considered as competing risks; the Gray test was used for univariate comparisons. Assessments of potential risk factors for outcomes of interest were evaluated in multivariate analyses using the Cox proportional hazards model. The variables considered in the multivariate analysis were stem cell source, cytogenetic risk, age, interval from diagnosis to transplant, year of transplant and kind of conditioning regimen. The type I error rate was fixed at 0.05 for the determination of factors associated with time-to-event outcomes; all tests were two-sided.
With a median follow up of 32 months (range 1-251), 108 patients died while in CR and 284 relapsed.
The 2-year cumulative incidence of relapse (RI) in the global population was 41 ± 3%. In univariate analysis, RI was significantly influenced by cytogenetic risk and age at transplant. The 2y-RI was 28 ± 7%, 43 ± 4% and 48 ± 8% for good, intermediate and poor risk patients, respectively (P o0.0002); patients older than 50 years showed a RI of 46 ± 6% compared to 39 ± 4% for younger patients (P = 0.024). Stem cell source (BM vs PBSCs) did not influence RI (41 ± 6% for BM and 41 ± 4% for PBSCs, P = 0.74), nor did kind of conditioning regimen used. In multivariate analysis, cytogenetic risk emerged as the only independent risk factor associated with The 2-year incidence of NRM in the overall population was 8 ± 2%. Older age was the only risk factor significantly associated with higher NRM both in univariate (11 ± 3% compared to 6 ± 2% for age above and below 50 years, respectively) and multivariate analysis (HR 1.036, 95% CI: 1.017-1.055, P o 0.0001). Stem cell source, year of transplant and conditioning regimen did not affect NRM risk.
LFS and OS probabilities at 2 years were 51 ± 3% and 65 ± 4%, respectively. Survival was significantly influenced by cytogenetic risk: 2-year LFS rates were 64 ± 8%, 48 ± 4% and 46 ± 7% in good, intermediate and poor risk patients, respectively (P o 0.0001), while the 2-year OS rates were 79 ± 7%, 63 ± 4% and 59 ± 8%, respectively (Po 0.0001, Figure 1 ). Older age emerged as a significant predictor of shorter 2-year LFS and OS (LFS: 55 ± 4% and 43 ± 5% in patients younger and older than 50 years, respectively, P o0.0001; OS: 69 ± 4% and 58 ± 5%, respectively, Po 0.0001, Figure 1 ). Like the other outcomes evaluated, survival rates were not affected by stem cell source. Multivariate analysis identified age and cytogenetic risk as independent risk factors associated with shorter LFS (age: HR 1.012, 95% CI: 1.004-1.020 P = 0.005; intermediate vs good risk: HR 1.5, 95% CI: 1.1-2 P = 0.013; poor vs good risk: HR 1.9, 95% CI: 1.4-2.7, Po 0.0001) and shorter OS (age: HR 1.016, 95% CI: 1.007-1.025, Po 0.0001; intermediate vs good risk: HR 1.7, 95% CI: 1.2-2.3, P = 0.004; poor vs good risk: HR 2.0, 95% CI: 1.4-3, P o0.0001).
Auto-HSCT was initially developed in the 1970s as an alternative treatment for patients lacking a sibling donor or unfit for allo-HSCT; 7 in the last decade, the broad use of HLA highresolution typing, 8 the availability of well-matched unrelated donors and the recent great development of T-cell replete haploidentical transplantation 9 have led to finding a donor for virtually all patients. On the other hand, the use of reduced intensity conditioning regimens makes today allo-HSCT feasible in elderly patients. In this complex scenario, auto-HSCT has become less popular in AML, representing today fewer than 10% of the auto-HSCT procedures performed in Europe, and its role in AML treatment needs to be redefined.
In our series of 809 patients transplanted in CR1, we observed remarkable 2-year LFS and OS rates of 51% and 65%, respectively. This is consistent with previous reports, 10 and should be regarded as a reference standard for future studies. All patients were evaluable for cytogenetic data, and we could therefore analyze outcome according to disease risk. Patients with good cytogenetics did particularly well, showing a strikingly low 2-year RI (28%), with LFS and OS of 64% and 79%, respectively. Those results deserve to be highlighted, as so-called 'good risk' AML represent a heterogeneous group bearing a relapse risk up to 40% following conventional chemotherapy. 11 Better outcome with auto-HSCT has already been reported in CBF, 12 NPM mutated 13 and CEBPA double mutated (CEBPAdm) 14 AML. Taken together, these findings support auto-HSCT as a valid strategy for consolidation of remission in patients with good risk cytogenetics.
Intermediate risk AML still represents a motley group with unclear outcome; if a matched sibling or unrelated donor is available, most centers prefer to perform allo-HSCT as consolidation of remission in this subset. However, despite a clear advantage in terms of LFS, there is still no evidence of better OS in patients receiving allo-HSCT compared to auto-HSCT in this setting. 4 In our series, intermediate risk patients autografted in first CR showed a RI of o50% at 2 years, with a LFS of 48% and OS of 63%; these results suggest that auto-HSCT is able to provide an acceptable outcome in intermediate risk AML. A limit of our study was the lack of molecular data in about 50% of patients assigned to the intermediate risk group, which might have altered the overall risk profile of this subpopulation.
Increasing age heavily influenced outcome in our series; older age was independently associated with higher NRM, together with significantly shorter leukemia-free and overall survival.
Unlike previous reports 15 we did not observe any impact of stem cell source on the outcomes evaluated in our study, suggesting that PBSCs represent a safe graft source for autologous transplant in AML.
In conclusion, given the inherent limits of this retrospective analysis, auto-HSCT should be considered as a main option in AML patients in first CR with good risk cytogenetics, and as a possible alternative to allo-HSCT in intermediate risk AML; however, patients older than 50 years need to be carefully selected, as older age appears to be associated with significantly higher NRM and worse survival. Prospective studies incorporating MRD assessment are needed to clarify the optimal role of auto-HSCT within AML post-remission strategy.
